Loading organizations...
§ Private Profile · San Diego, CA, USA
clinical-stage biopharmaceutical company developing dotinurad, a URAT1 inhibitor, for gout treatment in global Phase 3 trials.
Crystalys Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California, that develops novel prescription drug treatments for patients suffering from gout. The enterprise is currently advancing dotinurad, a URAT1 inhibitor that is already approved in certain Asian markets, through two comprehensive global Phase 3 clinical trials. To support this late-stage clinical development and regulatory strategy, the organization successfully secured a $205 million Series A financing round in June 2025. This significant capital injection was co-led by Novo Holdings and Catalys Pacific, with additional equity participation from prominent life science venture capital firms including SR One and Lightstone VC. The executive leadership team reunites experienced gout drug developers who previously held senior roles at major pharmaceutical corporations like AstraZeneca. Crystalys Therapeutics was founded in 2022 by James Mackay, BT Slingsby, Catalys Pacific, and Novo Holdings.
Crystalys Therapeutics has raised $205.0M across 1 funding round.
Crystalys Therapeutics has raised $205.0M in total across 1 funding round.
Crystalys Therapeutics has raised $205.0M across 1 funding round. Most recently, it raised $205.0M Series A in September 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 30, 2025 | $205M Series A | Ashwin RAM, Novo Holdings, SR ONE | Abrdn, Alexandria Venture Investments, AN Ventures, KB Investment, Lightstone Ventures, Longwood Fund, Perceptive Xontogeny Venture Fund, Pontifax, Prebys Ventures Fund, Wedbush Healthcare Partners | Announced |
Crystalys Therapeutics has raised $205.0M in total across 1 funding round.
Crystalys Therapeutics's investors include Ashwin Ram, Novo Holdings, SR One, abrdn, Alexandria Venture Investments, AN Ventures, KB Investment, Lightstone Ventures, Longwood Fund, Perceptive Xontogeny Venture Fund, Pontifax, Prebys Ventures Fund.